KSC · 068270.KS
Celltrion, Inc.
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
Loading market information…
TAI · 6446.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PharmaEssentia Corporation’s forward annual dividend is NT$1.50 per share, paid annual. The forward yield is 0.13% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
PharmaEssentia Corporation’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of NT$6.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PharmaEssentia Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 9, 2025 | NT$3.06+6.62% vs estimate | NT$3.26B-0.29% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | NT$3.36+15.86% vs estimate | NT$3.06B-1.29% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | NT$1.99-3.4% vs estimate | NT$2.71B-1.09% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
€78.55+€0.65 (+0.83%)
BioNTech SE’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
HK$79.75-HK$1.85 (-2.27%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.24% below the high.
$66.20-$0.08 (-0.12%)
Exelixis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
HK$424.80-HK$13.00 (-2.97%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 24.48% below the high.
$58.08+$0.68 (+1.18%)
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
$9.56-$5.25 (-35.45%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.8% below the high.
